HFSA’s 2026 Annual Scientific Meeting Is the Largest in Its History. Here’s What’s on the Agenda.
Heart failure affects millions of patients across the United States, and managing it well requires staying ahead of an evolving body of clinical evidence. This October, the Heart Failure Society of America’s Annual Scientific Meeting convenes in Phoenix, Arizona — October 9–12 at the Phoenix Convention Center — bringing together the full heart failure care team for what is shaping up to be the most comprehensive program in the event’s history. With more than 50 scientific sessions, 75 oral abstract presentations, 750 ePosters, and 300 faculty, HFSA ASM 2026 is the only major scientific meeting devoted exclusively to heart failure, and the scope of this year’s program reflects how quickly the field is moving.
Late-Breaking Trials Across the Full Spectrum of Heart Failure
The late-breaking science slate spans pharmacotherapy, imaging and diagnostics, and device-based therapy — covering both heart failure with reduced ejection fraction and the increasingly complex landscape of heart failure with preserved ejection fraction. Trials drawing particular attention include the Cycle-2 PEF Trial evaluating tovinontrine for HFpEF, the CARDIO-TTRansform trial focused on transthyretin amyloidosis, and data from the ReDS-SAFE HF II trial examining remote dielectric sensing-guided strategies for patients hospitalized with heart failure. The Gator SCALES-WHF trial, evaluating subcutaneous furosemide administration for worsening heart failure, rounds out a slate that the program committee has described as reflecting the pace of innovation currently transforming the field.
Device Innovation Takes Center Stage
Device-based therapies are receiving expanded focus this year, with a dedicated Devices in Heart Failure Meeting on October 9 alongside integrated device programming woven throughout the full four-day agenda. Real-world outcomes data from cardiac contractility modulation therapy and early-phase findings on subcutaneous cardiac microcurrent therapy are among the device-specific presentations expected to generate significant discussion. For interventional cardiologists managing heart failure patients alongside structural and coronary disease, the depth of device-focused content at HFSA 2026 makes this a particularly relevant conference year.
Why This Conference Matters for Regional Heart Failure Care
Heart failure management is a central part of Dr. Christopher Mallavarapu‘s clinical practice across Olean General Hospital and Northern Maine Medical Center. Staying current with the latest evidence — from outpatient decongestion strategies to emerging device therapies — directly influences the treatment decisions he brings to patients managing this condition. What gets presented in Phoenix this week will work its way into guidelines, clinical protocols, and ultimately into the conversations cardiologists have with heart failure patients at every level of the care system.
A Field Moving Faster Than Ever
Dr. Christopher Mallavarapu’s approach to heart failure care has always been grounded in evidence — adjusting treatment plans as the science evolves rather than defaulting to established convention. HFSA ASM 2026 is where a significant portion of that new evidence surfaces first, and for patients in communities where access to a cardiologist who follows the research closely makes a genuine difference, what happens in Phoenix matters well beyond the convention center walls.